CES 2026 recap: Morgan Stanley flags ’skyrocketing’ AI demand
This AI-picked telecom is up a whopping +77% in January’s first two sessions
Investors are likely to see this stock as ’next AI power play’: BofA
Futures flat, CES 2026 takes central stage- what’s moving markets
Investing.com -- NovaBridge Biosciences (NASDAQ:NBP) stock surged 19% in premarket trading Tuesday after the company reported positive data for its experimental gastric cancer treatment.
The biotech firm announced that its drug givastomig, when combined with nivolumab and chemotherapy, showed strong efficacy in first-line HER2-negative metastatic gastric cancer patients. The treatment demonstrated a 77% objective response rate (ORR) at the 8 mg/kg dose and 73% ORR at the 12 mg/kg dose across various PD-L1 and CLDN18.2 expression levels.
Patients receiving the 8 mg/kg dose achieved a median progression-free survival (PFS) of 16.9 months, while six-month landmark PFS rates were 73% for the 8 mg/kg cohort and 91% for the 12 mg/kg group. The company noted that data for the 12 mg/kg dose is still maturing with approximately four months shorter median follow-up.
The combination therapy was well-tolerated with a safety profile comparable to current standard of care treatments. The most common treatment-related adverse events included fatigue, nausea, and neutropenia, with immune-related gastritis observed in 33% of patients in each dosing cohort.
NovaBridge plans to initiate enrollment in a global, randomized Phase 2 study in the first quarter of 2026, evaluating both doses against standard of care. Detailed Phase 1b dose expansion data is expected to be presented at a medical conference later in 2026.
The company believes these results position givastomig as a potential best-in-class CLDN18.2-directed therapy for gastric cancer, which it estimates represents a $12 billion market opportunity by 2030.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
